Qnexa's Fate to Serve as a Guide for Other Obesity Drugs
By Mari Serebrov
Thursday, July 12, 2012
If the FDA greenlights Vivus Inc.'s Qnexa next week, it won't just be giving the market go-ahead to a second obesity drug. It will be opening up a new lane for weight-loss drugs containing an anticonvulsant.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.